Recombinant human erythropoietin is widely used to treat anemia associated with cancer and with the myelosuppressive effects of chemotherapy, particularly platinum-based regimens. Erythropoietin is the principal regulator of erythroid cell proliferation, differentiation, and apoptosis. Recently, the antiapoptotic and proliferative effects of erythropoietin on nonhematopoietic cells were also es...

PURPOSE Antineoplastic drugs, such as cisplatin (CDDP), are severely neurotoxic, causing disabling peripheral neuropathies with clinical signs known as chemotherapy-induced peripheral neurotoxicity. Cotreatment with neuroprotective agents and CDDP has been proposed for preventing or reversing the neuropathy. Erythropoietin given systemically has a wide range of neuroprotective actions in animal...

PURPOSE To assess physician use of erythropoietin in cancer patients before publication of the American Society of Clinical Oncology/American Society of Hematology guidelines. METHODS Questionnaires about erythropoietin use in practice and 12 hypothetical clinical scenarios involving patients with cancer were mailed to 2000 oncologists/hematologists in the United States and 19 other countries...

BACKGROUND Although erythropoietin has been used for decades in the treatment of anemia, data regarding endogenous levels in the general population are scarce. Therefore, we determined erythropoietin reference ranges and its clinical, biochemical and genetic associations in the general population. METHODS We used data from 6,777 subjects enrolled in the Prevention of REnal and Vascular ENd-st...

*Corresponding author: Ali Ghorbani, Department of Nephrology, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. E-mail: [email protected] Implication for health policy/practice/research/medical education: The initiation of erythropoietin therapy for the purpose of renoprotection may need to be sooner than that for erythropoiesis, because erythropoietin may...

BACKGROUND Studies suggest that in patients with heart failure (HF), high serum erythropoietin is associated with risk of recurrent HF and mortality. Trials of erythropoietin-stimulating agents in persons with kidney disease have also suggested an increased incidence of adverse clinical events. No large studies of which we are aware have evaluated the association of endogenous erythropoietin le...

BACKGROUND Recent evidence shows a selective destruction of the youngest circulating red blood cells (neocytolysis) trigged by a drop in erythropoietin levels. OBJECTIVE The aim of this study was to evaluate the effect of recombinant human erythropoietin beta on the red blood cell storage lesion and apoptosis indices under blood bank conditions. METHODS Each one of ten red blood cell units ...

(juirements.’ Changes in need are met in part by changes in the circulating red cell mass. Accordingly, erythropoietin has been demonstrated in the urine and plasma of patients with anemia or polycythemia of varying origin. However, investigations relating erythropoietin to erythropoiesis in normal mdividuals have only recently been made possible by improved assay methods. This study was undert...

We characterized the erythropoietin response to anemia among 73 HIV-infected and 246 uninfected twelve-month old infants in Malawi. Among HIV-infected and uninfected infants, the fitted regression line was log10 plasma erythropoietin = 2.66 –0.011*hemoglobin, and log10 plasma erythropoietin = 2.90 –0.013*hemoglobin, respectively, and the slope of the regression lines was similar (p = 0.42). The...

Regulation of the production of erythropoietin occurs in the kidney and liver largely through control of accumulation of erythropoietin mRNA. Erythropoietin mRNA was first detected in kidneys at 1.5 h postanemia and reached a plateau value at least 200-fold above the control value by 4 to 8 h. A 20-base sequence immediately upstream from the reported erythropoietin mRNA initiation site is compl...